

Research Project Proposal

Academic year 2024-2025

Project Nº 21

Title: Vaccination to improve the efficacy of CAR-T cells sin solid tumors

Department/ Laboratory

Laboratorios de "Terapia celular adoptiva" y "Terapia Génica para Cáncer" del Programa de "Inmunología e Inmunoterapia" y "Terapia Génica", respectivamente. Centro de investigación Médica Aplicada (CIMA).

Director 1 Sandra Hervás-Stubbs Contact: mshervas@unav.es Codirector: Contact:

Summary

Chimeric antigen receptor (CAR) T cells (CAR-T) represent a revolutionary treatment for hematological tumors but their efficacy in solid tumors has not been yet supported. The efficient activation and expansion of CAR-T cells *in vivo* is key for the success of CAR-T therapy. Both phenomena are highly dependent on the recognition of the tumor antigen (Ag). For solid tumors, CAR-targeted Ag (CAR-Ag) recognition occurs exclusively in the tumor microenvironment (TME). However, the immunosuppressive TME prevents the efficient activation and expansion of CAR-T cells. We believe that off-tumor recognition of CAR-Ag could exert a boosting effect and substantially improve the efficacy of CAR-T therapy in solid tumors. This could be safely achieved with companion vaccines expressing the CAR-Ag. The mRNA molecule is a versatile drug class that can encode proteins with therapeutic interest, including tumor Ags. Self-amplifying (sa)RNA is a new platform which uses similar technology to mRNA but with the added ability to self-amplify, thereby resulting in higher protein levels per dose. Most saRNA vaccines are based on the genomic RNA of an alphavirus. The goal of this project is to study the therapeutic effect of CAR-T cells in combination with (sa)RNA vaccines encoding for the CAR-Ag.

For that purpose, the following partial objectives are proposed: (1) Production of a (sa)RNA vaccine expressing the CAR-Ag or Luciferase (as reporter protein); (2) To study the in vivo expression of proteins encoded by the (sa)RNA vaccine using bioluminescence imaging and compare different vaccine administration routes, (2) To study the boost effect of the (sa)RNA vaccine on CAR-T cells in vivo; (4) Evaluate the antitumoral activity of the CAR-T-cell/vaccine combination in breast tumour models.

The project will involve the use of many different techniques, including Molecular Biology, cell culture, RNA synthesis, analysis by flow cytometry, immunological techniques, animal models of cancer, monitorization of immune responses etc.

Does the project include the possibility of supervised animal manipulation to complete the training for animal manipulator?

yes	\checkmark
no	
L	